Results 181 to 190 of about 11,226 (207)
Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial. [PDF]
Nat CommunOstendorf L +15 more
europepmc +1 more source
Cancers, 2021 Daratumumab is active both as a single agent and in combination with other agents in multiple myeloma (MM) patients. However, the majority of patients will develop daratumumab-refractory disease, which carries a poor prognosis. Since daratumumab also has
Kristine A Frerichs +2 more
exaly +3 more sources
MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins
Clinica Chimica Acta, 2019 Daratumumab, a therapeutic IgG kappa monoclonal antibody, can cause a false positive interference on electrophoretic assays that are routinely used to monitor patients with monoclonal gammopathies.
Katie L Thoren
exaly +2 more sources
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference [PDF]
Clinical Chemistry and Laboratory Medicine, 2016 BACKGROUND: Monoclonal antibodies are promising anti-myeloma treatments. As immunoglobulins, monoclonal antibodies have the potential to be identified by serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE).
Christopher R Mccudden +2 more
exaly +2 more sources
Clinical Chemistry and Laboratory Medicine, 2016 Contains fulltext : 172840.pdf (Publisher’s version ) (Open Access)Daratumumab is a fully human anti-CD38 IgG1-kappa monoclonal antibody (mAb) currently being evaluated in several Phase 2 and 3 clinical studies for the treatment of ...
, Henny G Otten, A Kate Sasser
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Daratumumab for the Treatment of Multiple Myeloma [PDF]
Frontiers in Immunology, 2018 This mini-review will summarize the present state of development of the CD38 antibody daratumumab for the treatment of multiple ...
Torben Plesner +2 more
exaly +2 more sources